



Australian Government

Department of Health
and Aged Care



Australian
Centre for
Disease
Control

2025 • Volume 49

Communicable Diseases Intelligence

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2023

Christiane Stehmann, Matteo Senesi, Shannon Sarros, Amelia McGlade, Victoria Lewis,
Priscilla Agustina, Laura Ellett, Daniel Barber, Genevieve Klug, Catriona McLean, Colin L Masters,
Steven Collins

Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Security & Emergency Management Division, Department of Health and Aged Care.

The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2025 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence

This publication is licensed under a Creative Commons Attribution-Non-Commercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

- the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found on the Department of Prime Minister and Cabinet website;
- any logos (including the Department of Health and Aged Care's logo) and trademarks;
- any photographs and images;
- any signatures; and
- any material belonging to third parties.

Disclaimer

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

Enquiries

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au.

Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.

Editor

Christina Bareja

Deputy Editor

Simon Petrie

Design and Production

Lisa Thompson

Editorial Advisory Board

David Durrheim, Mark Ferson, Clare Huppertz, John Kaldor, Martyn Kirk and Meru Sheel

Submit an Article

Submit your next communicable disease related article to CDI for consideration. Information for authors and details on how to submit your publication is available on our website, or by email at cdi.editor@health.gov.au.

Contact us

Communicable Diseases Intelligence (CDI)
Health Security & Emergency Management Division
Department of Health and Aged Care
GPO Box 9848, CANBERRA ACT 2601

Website: www.health.gov.au/cdi

Email: cdi.editor@health.gov.au

Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2023

Christiane Stehmann, Matteo Senesi, Shannon Sarros, Amelia McGlade, Victoria Lewis, Priscilla Agustina, Laura Ellett, Daniel Barber, Genevieve Klug, Catriona McLean, Colin L Masters, Steven Collins

Abstract

Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable developments have occurred in pre-mortem diagnostics; in the delineation of new disease subtypes; and in heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2023.

Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of referrals has steadily increased. In 2023, a total of 651 domestic CSF specimens were referred for diagnostic testing and 83 persons with suspected human prion disease were formally added to the national register. As of 31 December 2023, just under half of the 83 suspect case notifications (41) remain classified as 'incomplete'; 10 cases were classified as 'definite' and 28 as 'probable' prion disease; three cases were excluded through neuropathological examination and one was removed from the register as 'unlikely CJD' after clinical evaluation. For 2023, fifty-three percent of all suspected human-prion-disease-related deaths in Australia underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified.

Keywords: Creutzfeldt-Jakob disease; prion disease; transmissible spongiform encephalopathy; disease surveillance

Introduction

Of the human prion diseases (also known as transmissible spongiform encephalopathies), the most common is Creutzfeldt-Jakob disease (CJD). As described previously,¹ human prion disease mostly arises sporadically, but can occur through person-to-person transmission or from a genetic aetiology. The Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR) was established in 1993 as part of the response to four people dying from CJD related to fertility treatment utilising cadaveric pituitary hormones. In the following year, the Allars

inquiry² released its findings into the use of cadaver-derived pituitary hormones under the Australian Human Pituitary Hormone Program and the association with four medically-acquired (iatrogenic) CJD (iCJD) deaths, recommending a broadening of the responsibilities of the then nascent ANCJDR. In addition to monitoring for further cases of iCJD in Australia, related to cadaveric pituitary hormone treatment for infertility or short stature and contaminated dura mater grafts, the ANCJDR's activities have evolved to encompass the surveillance of all

types of CJD, including sporadic, genetic and variant CJD (vCJD: the zoonosis related to bovine spongiform encephalopathy [BSE]), as well as other prion diseases such as Gerstmann-Sträussler-Scheinker syndrome and fatal sporadic or familial insomnia. Human prion disease became a notifiable disease in all states and territories of Australia as of June 2006.

Initial case awareness at the ANCJDR mostly arises through diagnostic testing requests made to the ANCJDR; this occurs prior to Health Department notification. After a preliminary review of referred cases, those deemed to be genuine suspected human prion disease undergo further detailed evaluation and addition to the national surveillance register, to determine whether a case can be excluded from suspicion or can be classified as ‘definite’, ‘probable’ or ‘possible’ prion disease according to diagnostic criteria endorsed by the Creutzfeldt-Jakob Disease International Surveillance Network (colloquially EUROCJD) and to determine the aetiology of the illness.³

The incidence of sporadic CJD (sCJD) is commonly reported to be approximately one case per million per year; however, in most countries with longstanding surveillance systems in place, annual incidence rates have been consistently reported above this quoted figure.⁴ A multi-national surveillance study showed that intensity of surveillance correlates with reported incidence rates.⁵ Temporally, human prion disease incidence rates have increased in most countries, including Australia, as surveillance mechanisms have been optimised and diagnostic testing capabilities improved, in parallel with a generally greater awareness of this rare disease in the health-care setting.

In this report, updated national surveillance figures to 31 December 2023 are provided for all retrospective (to 1970) and prospective (from 1993) cases ascertained (Table 1), including a discussion on case notifications, classifications and overall incidence.

Table 1: Overall summary of Australian human prion disease, 1 January 1970 to 31 December 2023

Classification	Sporadic	Familial	Iatrogenic	Variant CJD	Unclassified/ Indeterminate	Total
Definite	742	68	5 ^a	0	0	814
Probable	478	37	4	0	0	519
Possible	15	2	1	0	0	18
Incomplete	0	9	0	0	204	213
Total	1,235	116	9	0	204	1,564

a Includes one definite iatrogenic case who received pituitary hormone treatment in Australia, but disease onset and death occurred while a resident of the United Kingdom. This case is not included in statistical analysis since morbidity and mortality did not occur within Australia.

Surveillance methods

Patients with suspected human prion disease have been prospectively notified to the ANCJDR since October 1993. From 1997 onwards, suspected cases have been increasingly notified through referral for cerebrospinal fluid (CSF) 14-3-3 testing, which has over time become the predominant source of initial ANCJDR awareness of suspected CJD cases. Other ascertainment mechanisms include, or have included, personal communications from clinicians, families, hospitals and CJD-related groups, as well as health record searches through hospitals and health departments.

Once referred to the ANCJDR, referrals undergo a *prima facie* assessment and, if the suspicion of prion disease is supported, the case is notified to the appropriate health department and added to the ANCJDR register as a formal ‘suspected case’ for continued surveillance and evaluation with the aim of exclusion or classification according to EUROCJD-endorsed diagnostic criteria. Investigation of registered cases can be prolonged, as the ANCJDR requires next-of-kin consent to access and compile the appropriate clinical information from various health information sources to facilitate a comprehensive review.

Response times can vary, as the information can be extensive or sources numerous. Medico-demographic questionnaires are offered and forwarded to families, if they are willing to contribute, providing valuable information for analysis and evaluation.

Classification of registered cases remains as 'incomplete' until all known available information is gathered and reviewed, or until a definitive result from neuropathological assessment is obtained. Cases may be excluded from the register based on neuropathological examination or after thorough clinical evaluation. A 'definite' classification requires brain neuropathological examination, including immunohistochemical analysis; 'probable' and 'possible' cases are reliant on a specific clinical profile and diagnostic test outcomes being met as previously described.³ As of 1 January 2017, the diagnostic criteria for 'probable sporadic CJD' were amended to include a positive result in the real-time quaking-induced conversion (RT-QuIC) assay using CSF or other tissues in a person with a progressive neurological syndrome. The updated EUROCD diagnostic criteria for surveillance of sporadic CJD are listed in Appendix A. In keeping with previous reports, the total number of confirmed prion disease cases for 2023, including for statistical analyses, are those that have been classified as 'definite' or 'probable' cases.

To support surveillance responsibilities, the ANCJDR provides diagnostic platforms for ante- and post-mortem testing for human prion diseases. The testing of CSF for the presence of a family of low-molecular-weight proteins (14-3-3) has been performed weekly by the ANCJDR since 1997. This test has been readily utilised by clinicians. In 2023, the ANCJDR replaced the semi-quantitative 14-3-3 western blot analysis with a more accurate and quantitative technology, estimation of 14-3-3 protein concentrations using an Enzyme Linked Immunosorbent Assay (ELISA) (recently certified by the National Association of Testing Authorities [NATA]/International Laboratory Accreditation Cooperation [ILAC]).⁶

In 2017, the ANCJDR formally added estimation of CSF total-tau protein concentrations, which was also NATA/ILAC accredited, for the diagnosis of human prion disease. The concentration of total-tau protein in CSF was measured by Roche Elecsys® technology.ⁱ Since 2021, the RT-QuIC assay has been performed routinely on all CSF specimens referred for diagnostic testing when sufficient sample volume allows, with this diagnostic platform also very recently NATA/ILAC certified. The ANCJDR also undertakes western blot analysis for misfolded, protease-resistant prion protein in brain and tonsil tissue from biopsies or autopsies for supplementary immunohistochemical assessments, as required for diagnostic and subclassification purposes. Prion protein gene (*PRNP*) testing for sequence variations in the open reading frame, particularly for proven disease-causing mutations, is performed by an external independent provider as appropriate. Upon request, the ANCJDR performs DNA extractions from frozen post-mortem brain tissue, which can be used for *PRNP* testing. The ANCJDR actively promotes all diagnostic tests to clinicians and families to achieve the most accurate diagnosis and classification of persons suspected to suffer from prion disease.

Annual human prion disease incidence rates are calculated using direct age-standardisation, based on the 1970–2023 Australian Bureau of Statistics estimated resident population data for Australia and for each state and territory.ⁱⁱ Health information is collected through a combination of public health and surveillance responsibilities, based on the national notification of communicable diseases in observance of the *National Health Security Act 2007* and *Privacy Act 1988 (Cth)* 16B. ANCJDR surveillance activities for 2023 were approved by The University of Melbourne Human Research Ethics Committee (#20361).

i Roche Diagnostics. The power of Elecsys® in Alzheimer's disease. [Internet.] Basel: Roche Diagnostics; 2022. Available from: <https://diagnostics.roche.com/global/en/article-listing/health-topics/neurology/the-power-of-elecsys-in-alzheimers-disease.html>.

ii Australian Bureau of Statistics. 3101.0 National, state and territory population - June 2023. Tables 51-59. Accessed 1/02/24. Available from <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release#data-download>.


Results

In 2023, the ANCJDR received 651 domestic CSF specimens for diagnostic testing. This number reflects a continuing positive trend in annual CSF referral numbers and represents an increased awareness and perceived utility of CSF diagnostic testing by clinicians (Figure 1). In 2023, non-domestic CSF referrals made up 6% of the total diagnostic CSF specimens received by the ANCJDR; the total number of non-domestic CSF test referrals has also steadily increased over time. The majority of domestic CSF referrals come from the most populous states, in which there has been a noticeable steady increase in test referrals, while CSF referrals from the Australian Capital Territory, the Northern Territory and Tasmania have remained relatively unchanged. Notably, diagnostic test referrals from New South Wales have increased more rapidly over the last decade than those from all other states, increasing from an average referral rate of 12/million/year (1997–2012) to 24/million/year (2013–2023). The national average CSF referral rate for the period of 1997–2023 is 15/million/year; the Northern Territory has the lowest rate of CSF referrals (4/million/year), while all other states range from 10/million/year (Western Australia) to 17/million/year (Tasmania).

During 2023, eighty-three persons with suspected human prion disease were formally added to the national CJD surveillance register following *prima facie* review. Of these, five cases were known to the ANCJDR prior to 2023 through CSF referrals (2), the CJD Support Group Network (2) and neuropathology services (1). At the time of their initial notification in 2021 and 2022, these cases were not added to the register due to a low level of suspicion for prion disease after initial case review. Further information ascertained in 2023 increased the likelihood of prion disease, resulting in formal notification and addition of the cases to the register. These five cases therefore contribute to the total numbers of suspect case notifications arising in 2021 and 2022.

The remaining 78 suspected cases for 2023 were initially notified via: request for CSF diagnostic testing (44 cases); communications from clinicians (24 cases); the CJD Support Group Network (5 cases); neuropathology services (2 cases); and health departments, hospitals and genetic counselling services (1 case each). While there is still a predominance of initial case awareness through referrals for CSF diagnostic testing, there has been in recent years a

Figure 1: Annual number of CSF specimens referred to the ANCJDR for diagnostic testing, from 1997 to 2023



noticeable increase in case notifications through treating clinicians, neuropathologists, health departments and families seeking expert advice and guidance from the ANCJDR. Some previous proactive ANCJDR surveillance mechanisms (e.g. mortality database searches and reply-paid mailouts to clinicians) have been discontinued over time due to human resource constraints.

The number of suspected cases added to the ANCJDR register in 2023 follows the trend of increasing case notification rates. The average annual number of prospective, formal suspect prion disease cases notified to the ANCJDR for the period 1997–2023 (i.e. since the introduction of diagnostic testing of CSF) is 74. States and territories exhibited modest fluctuations in the annual number of suspect case notifications for 2023, compared to both the previous year and the longer-term average (Table 2).

Of the 78 formal suspect case notifications added in 2023, eight cases were confirmed as ‘definite’ by neuropathological examination and 26 cases were classified as ‘probable’ following detailed review of clinical information. Two cases were confirmed as non-prion disease following neuropathological assessment and one case was removed from the surveillance register after clinical case review, while 18 cases were still alive and considered ‘incomplete’ at the end of 2023; neuropathology reports were

pending for 23 deceased suspected cases. It is typical for several months to elapse between performance of a post-mortem and completion of the neuropathology report.

Since 1993, there has been an overall positive trend in the annual number of suspected cases of human prion disease undergoing post-mortem brain examination, or less commonly brain biopsies, albeit with relative plateauing over the last 15 years; beginning with twelve such cases in 1993 and increasing to between 30 and 50 brain autopsy referrals per year for the period from 2005 to 2023 (Figure 2). In 2023, of the 72 suspected CJD case deaths, 38 were referred for a brain post-mortem examination.

Of suspected prion disease cases added to the register between 1993 and 2023, the average annual proportion undergoing post-mortem brain examination is 59% (range 40–69%); the provisional proportion for 2023 is 53%. Annual suspected prion disease brain autopsy referrals by states and territories over the period 1993–2023 display considerable fluctuation in each jurisdiction. In the more populous states, there has generally been an overall temporal increase in brain autopsy referrals. In regions with smaller populations, this positive trend is also present but less robust due to the relative impact of variation in the annual brain autopsy referrals caused by small population sizes and case numbers.

Table 2: ‘Definite’ and ‘probable’ cases of human prion disease from 1993 to 2023, by year and state or territory


Jurisdiction ^b	2023 ^a		1993–2023		
	Cases	ASMR ^c (dths/mill/yr)	Total cases	Long term average cases	Average ASMR (dths/mill/yr)
ACT	1	1.33	17	0.6	1.28
NSW	10	0.95	351	11.3	1.43
NT	0	0	7	0.2	0.75
Qld	13	1.71	191	6.2	1.21
SA	5	1.99	96	3.1	1.67
Tas.	1	1.48	24	0.8	1.16
Vic.	5	0.62	289	9.3	1.59
WA	8	1.93	145	4.7	1.79
Australia	43	1.24	1,120	36.1	1.47

a The figures for 2023 are provisional and almost certainly an underestimate, as 25 neuropathology reports are pending and two cases who died in 2023 remain under investigation.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

c ASMR: age-standardised mortality rate, in deaths per million population per year.

Figure 2: Number of brain-only post-mortem (PM) examinations and brain biopsies (BBx) completed relative to suspect case deaths from 1993 to 2023, by year




As of 31 December 2023, there were 1,564 cases on the ANCDJR register, with 1,333 of these classified as ‘probable’ or ‘definite’ prion disease cases. An additional ‘definite’ iatrogenic case, who was treated in Australia but died in the UK, is included in Table 1; this case is not classified as an Australian case due to their location at death and is thereby excluded from the overall statistical analysis of Australian prion disease cases. Since the start of prospective surveillance in 1993, a total of 887 suspected prion disease cases have been removed from the register through neuropathological assessment or after detailed clinical review.

In 2023, twenty-four cases were re-classified from ‘incomplete’ to ‘definite’ prion disease and forty-four cases to ‘probable’ prion disease. One ‘possible’ case of likely sporadic prion disease was classified in 2023. In 2023, the total number of ‘incomplete’ cases under evaluation was slightly lower than in 2022. Ten cases were assigned the label of ‘indeterminate’ as they could not be classified confidently using the EUROCD-endorsed diagnostic criteria after detailed clinical review. Impediments to timely and complete access to all clinical information, especially MR brain imaging, can limit confident case classifications.

The age-standardised mortality rate (ASMR) for prion disease for 2023 was 1.24 deaths per million per year. This figure is provisional and almost certainly an underestimate, as 25 neuropathology reports are pending and two cases who died in 2023 are remaining under investigation. Annual ASMR values for human prion disease in Australia during the period of 1970 to 2023 have generally increased. The mean annual ASMR during the period from 1970 to 2023 is 1.13 death per million (range 0.1–2.3). For the prospective surveillance period of 1993 to 2023, the annual mean ASMR is 1.47 deaths per million (range 0.7–2.3). By state and territory, most regions in Australia have an annual mean ASMR equivalent to or above one case per million per year between 1993 and 2023 (Table 2), except for the Northern Territory. The lower rates of ascertainment in the Northern Territory may be partly explained by geographical challenges relating to proximity to specialised health care and post-mortem services, as illustrated in CSF diagnostic test referral rates and autopsy referral rates well below the national average.

Figure 3: Human prion disease in Australia from 1993 to 2023; number of cases and age-standardised mortality rates (ASMR), by year



A breakdown of annual case numbers and mortality rates is shown in Figure 3 and Table 2. The highest annual number of ‘probable’ and ‘definite’ prion disease cases reported, since surveillance commenced in 1993, was 73 in 2020, resulting in an annual ASMR of 2.28 deaths per million. Higher mortality rates, ranging between 1.7 and 2.3, have been recorded since 2016; this coincides with the introduction of new diagnostic tools, such as CSF tau estimation, the RT-QUIC assay and improved understanding of suggestive magnetic resonance (MR) brain imaging findings.


The proportions of human prion disease aetiologies on the ANCJDR register for 2023 remained similar to previous years (Figure 4); the vast majority of the 1,333 statistical cases of human prion disease are ‘sporadic’ (91.5%) while genetic and iatrogenic cases represent 8.5% and < 1%, respectively, of all ‘definite’ and ‘probable’ cases. No case of vCJD has yet been confirmed, including during 2023.

There are currently 1,220 ‘definite’ and ‘probable’ sporadic prion disease cases on the ANCJDR register. The distribution is almost equal between males (48.5%) and females (51.5%), with the slight

predominance in females reflecting their longer life expectancy. The average age at death is 67.6 years, with a median of 69 years, ranging in age from 19 to 91 years. The average duration of illness is 6.3 months, with a median of 3.9 months, ranging from 0.9 to 60 months.

There are currently 67 families affected by genetic prion disease on the ANCJDR register, comprising 105 individuals (68 ‘definite’ and 37 ‘probable’ cases) with a confirmed genetic aetiology, 55% of whom were female. The average age at death for genetic prion disease is approximately a decade younger than in sporadic prion disease, at 57.9 years, with the median of 60 years, ranging from 18 to 83 years; the average duration of illness is approximately 9 months longer than in sporadic prion disease, at 15.1 months, with a median of 5.9 months, ranging from 1.3 to 192 months. Age of onset and duration of illness depend on the mutation present and its resulting phenotype; fatal familial insomnia and Gerstmann-Sträussler-Scheinker syndrome are often associated with younger age of onset and longer durations than mutations resulting in CJD-like presentations.

Figure 4: ‘Definite’ and ‘probable’ human prion disease cases 1970 to 2023,^a by year and aetiology



^a Includes one definite iatrogenic case who received pituitary hormone treatment in Australia but disease onset and death occurred while a resident of the United Kingdom.

To date, three prion protein gene (*PRNP*) mutation carriers had been excluded from the register after brain autopsy. They died aged 70, 88 and 91 years old, well above the average age at death of their pedigrees. Nine incomplete cases remain under investigation on the register without a neuropathological or clinical case classification outcome; however, there is documented concern for genetic prion disease. Four families are of unspecified *PRNP* status, although there is a recorded family history of prion disease. The range of *PRNP* mutations in Australian genetic prion disease cases is shown in Table 3. In 2023, four cases of genetic prion disease were confirmed neuropathologically or by clinical case evaluation. The utility of diagnostic biomarkers for genetic prion disease, especially those found in CSF, continues to be defined.⁷

In 2023, two cases of octapeptide insert mutations (OPRI) were identified through genetic counselling services. One case (6 OPRI) had a previously documented strong family history of ‘fronto-temporal dementia’ (FTD), which had been neuropathologically reported as ‘u-FTD’. A next generation sequencing panel did not find an associated FTD mutation, but genetic sequencing of a family member identified a *PRNP* OPRI mutation. Follow-up investigation of frozen and fixed brain tissue of one family member documented the presence of a 6 OPRI mutation, with PrP^{Sc} confirmed in western blot and RT-QuIC. The second (9 OPRI) case, adopted in childhood without a documented family history of neurodegenerative disease, presenting with a history of neuropsychiatric changes was diagnosed after Sanger sequencing of the *PRNP* gene. These cases highlight the importance of genetic testing, including Sanger sequencing for *PRNP* insert mutations, in less typical neurodegenerative diseases to accurately diagnose cases of progressive dementias when a clear causal genetic explanation has not been uncovered.^{8,9}

Table 3: Prion protein gene (PRNP) sequence variations/mutations identified in Australian cases

Mutation/polymorphism	Definite/probable cases	Cases PM proven Not CJD
E200K	49	3
D178N	17	0
V210I	8	0
P105T	6	0
P102L	6	0
Insert mutations/OPRI ^a	6	0
Other mutations ^b	8	0
Not determined	5	0
Total	105	3

a OPRI: abbreviation for octapeptide repeat insertion.

b A133V, E200D, E211D, G131V, T188A, V176G, V180I, V189I.

Discussion

In 2023, the number of suspected prion disease referrals and confirmed cases broadly matched the long-term average (1997–2022). Australia continued to be free of vCJD and there were no further cases of iCJD detected. By state and territory, the numbers of suspected case referrals showed generally only modest fluctuations during 2023 compared to previous years; the fluctuations seen in 2023 are within previously observed ranges.

Long-term national surveillance units report differing annual prion disease mortality rates, ranging from 0.24 to 4.56 per million population.⁴ Higher rates of human prion disease over short time frames have also been recognised and investigated in various global settings with inconclusive outcomes.¹⁰ The underlying basis for fluctuations and differences in national mortality rates is uncertain, although variation in case ascertainment is one potentially contributing factor.⁵ Spatio-temporal clustering of CJD has previously been recognised in New South Wales and Victoria.^{11,12} Detailed epidemiological assessment by the ANCJDR did not disclose any likely horizontal transmission event, but instead uncovered a heightened intensity of surveillance. This more intense level of surveillance was reflected by the significantly higher rates of referrals of suspect prion disease cases for evaluation and diagnostic testing to the ANCJDR, as well as higher neuropathological examination rates in suspected patients. Monitoring of the geographical distribution of suspected case referrals

and confirmed cases remains an important facet of ANCJDR national surveillance. An overall increase in sporadic CJD cases has also been observed in Australia and is most likely due to a combination of an ageing population, improved case ascertainment and diagnostic methodologies, and greater awareness of prion disease in the healthcare sector. The gradual increase in the incidence of sCJD, but not that of genetic CJD, has also been reported in other countries with longstanding prion disease surveillance and supports the notion that it is at least partly a result of the globally ageing population.^{13,14}

Ascertainment mechanisms in 2023 were unchanged compared to recent years, with the majority of initial referrals coming through requests for diagnostic CSF testing. Some proactive ascertainment mechanisms (such as state health department and tertiary hospital mortality data base searches) have ceased, while other case detection methods have increased. The number of CSF referrals to the ANCJDR for diagnostic testing remained high for 2023. A 20% increase in diagnostic test referrals coincided with the introduction of CSF total-tau protein estimation and the identification of misfolded prion protein in CSF by RT-QuIC in 2017. Since 2021, the ANCJDR, as per an amended contract with the Australian Government Department of Health and Aged Care, ceased its cost recovery for CSF diagnostic testing for domestic specimens, which may have contributed to a ~10% year on year increase in test referrals.

The ANCJDR continues to evaluate optimal diagnostic investigations and their specific parameters, with a recent study confirming recent suggested amendments to criteria for a magnetic resonance imaging (MRI) scan to be considered supportive of sporadic CJD being at least as good as extant criteria.¹⁵

The proportion of post-mortem examinations being performed in suspected prion disease cases remains high and aligns with the long-term mean brain autopsy percentage of approximately 60% (of suspected case deaths) between 1993 and 2023. This contrasts with the findings of an Australian health-care setting survey where the national hospital post-mortem rate was 12% in 2002–2003;¹⁶ more recently, a major Australian tertiary centre audit of hospital autopsy data has described an autopsy rate of 6.6% in 2011–2013.¹⁷ The high suspected prion disease-related post-mortem rate underpins the high and consistent number of confirmed Australian human prion disease cases recorded over the more recent prospective surveillance epoch and provides confident understanding of the cause of death in suspected cases ultimately determined as non-prion disease. The consistent use of diagnostic RT-QuIC technology on CSF, with high specificity and good sensitivity, may be contributing to a modest decline in autopsy referral rates from over 60% to 53% in 2023. This trend has also been observed in other international prion surveillance units.^{iii,iv}

A recent study by the ANCJDR, of prion disease in Indigenous Australians, has confirmed that sporadic CJD occurs in Indigenous Australians throughout Australia with a phenotype and incidence rate equivalent to non-Indigenous Australians, supporting the adequacy of national human prion disease surveillance.¹⁸

No further iCJD cases were confirmed in Australia during 2023. The most recent human cadaveric pituitary gonadotrophin-related CJD death occurred in 1991, while the most recent Lyodura-related CJD death occurred in 2000. In 2023, the United States of America reported one iCJD case, associated with growth hormone treatment and a 50-year incubation period.^v

iii Personal communication, National Prion Disease Pathology Surveillance Center (Case Western Reserve University; Cleveland, Ohio, United States of America).

iv Personal communication, National Creutzfeldt-Jakob Disease Research and Surveillance Unit (Western General Hospital; Edinburgh, Scotland, United Kingdom).

v Personal communication, Centers for Disease Control and Prevention (United States Government Department of Health and Human Services, Atlanta, Georgia, United States of America).

Since vCJD was first reported in 1996, a total of 233 patients, from 12 countries, have been identified with this disease. Case 178 from the United Kingdom (UK) was methionine-valine heterozygous at codon 129 of the *PRNP* gene;¹⁹ all cases previously had been methionine homozygous at codon 129. The patient was 36 years old when he presented with psychiatric symptoms prior to onset of neurological features that included cognitive decline, ataxia and myoclonus, dying after an illness of 20 months. CSF 14-3-3 and RT-QuIC were negative. Brain MRI revealed features more typical of sCJD (bilateral high signal in basal ganglia) without any posterior thalamic high signal ('pulvinar sign'). The patient did not meet the epidemiologic diagnostic surveillance criteria for 'probable' or 'possible' vCJD, although fulfilled criteria for 'probable' sCJD; neuropathology, including western blot glycotyping, was typical of vCJD. It remains uncertain whether this case marks the start of a second wave of vCJD affecting those heterozygous for methionine-valine at codon 129. This case also underscores the importance of performing suspect CJD brain autopsy examinations and the benefits of maintaining high-level surveillance within Australia. The most recent three vCJD cases, who died in France in 2019 and 2021 and Italy in 2016, are plausibly related to accidental occupational exposure incidents in laboratory settings.^{14,20}

The horizontal transmission of amyloid beta ($A\beta$) peptides associated with Alzheimer's disease through contaminated pituitary hormone treatments and dura mater grafts is essentially proven,^{21–23} with the likelihood that contaminated neurosurgical instruments may also be a source of transmission.²⁴ It is also becoming increasingly accepted that such inadvertent inoculation can eventuate many years later in a disease phenotype, including cerebral amyloid angiopathy(CAA)-related intra-cranial haemorrhage,²⁵ and probably Alzheimer's disease.²⁶ Prion protein and $A\beta$ protein share similar properties, such as prion-like mechanisms of template-directed protein propagation, as well as inter-cellular spread of the misfolded protein isoforms and formation of larger fibrils. The slow propagation is associated with prolonged incubation periods before these proteins result in overt clinical and pathological evidence of disease following inoculation. In 2021, a comprehensive database search at the Royal Melbourne Hospital identified three young adult patients presenting with spontaneous intra-cranial haemorrhage due to early-onset CAA (confirmed pathologically in two).

All three had undergone childhood neurosurgery with use of Lyodura (dura mater) grafts confirmed in two and likely to have been used in the third patient supporting the likelihood of early-onset CAA due to transmission of A β peptides from contaminated Lyodura, with the findings recently published.²⁷

Acknowledgments

The ANCJDR wishes to thank families, as well as medical practitioners and associated staff, for their generous support of Australian CJD surveillance. The ANCJDR also thanks Associate Professor Handan Wand, Professor Matthew Law and Professor John Kaldor (The Kirby Centre; formerly the National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales) for their expert ad hoc epidemiological and statistical support, as well as the CJD Support Group Network for their assistance in surveillance activities.

Author details

Dr Christiane Stehmann – Coordinator,
Australian National Creutzfeldt-Jakob
Disease Registry (ANCJDR)¹

Dr Matteo Senesi – Research Fellow,
ANCJDR²

Ms Shannon Sarros – Research Assistant,
ANCJDR¹

Ms Amelia McGlade – Research Assistant,
ANCJDR¹

Dr Victoria Lewis – Research Fellow,
ANCJDR²

Dr Laura Ellett – Research Officer, ANCJDR¹

Ms Priscilla Agustina – Research Assistant,
ANCJDR¹

Dr Daniel Barber – Neurologist, ANCJDR¹

Ms Genevieve Klug – Research Assistant,
ANCJDR²

Professor Catriona A McLean –
Neuropathologist, ANCJDR^{1,3}

Professor Colin L Masters – Director,
ANCJDR¹

Professor Steven J Collins – Director,
ANCJDR^{1,2}

1. The Florey Institute, The University of Melbourne, Victoria, 3010, Australia
2. Department of Medicine, The University of Melbourne, Victoria, 3010, Australia
3. The Alfred Hospital, Department of Anatomical Pathology, 55 Commercial Rd, Melbourne Vic 3004 Australia

Corresponding author

Prof Steven Collins

Australian National Creutzfeldt-Jakob
Disease Registry, Department of Medicine,
The University of Melbourne, Victoria, 3010,
Australia.

Telephone: +61 8344 1949.

Facsimile: +61 9349 5105.

Email: s.collins@unimelb.edu.au

References

1. Klug GM, Boyd A, Sarros S, Stehmann C, Simpson M, McLean CA et al. Creutzfeldt-Jakob disease surveillance in Australia, update to December 2013. *Commun Dis Intell Q Rep*. 2014;38(4):E348–55.
2. Allars M. *Report of the inquiry into the use of pituitary derived hormones in Australia and Creutzfeldt-Jakob disease*. Canberra: AGPS, 1994.
3. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Brain*. 2009;132(10):2659–68. doi: <https://doi.org/10.1093/brain/awp191>.
4. Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. *Lancet Infect Dis*. 2020;20(1):e2–10. doi: [https://doi.org/10.1016/S1473-3099\(19\)30615-2](https://doi.org/10.1016/S1473-3099(19)30615-2).
5. Klug GM, Wand H, Simpson M, Boyd A, Law M, Masters CL et al. Intensity of human prion disease surveillance predicts observed disease incidence. *J Neurol Neurosurg Psychiatry*. 2013;84(2):1372–7. doi: <https://doi.org/10.1136/jnnp-2012-304820>.
6. Senesi M, Lewis V, Varghese S, Stehmann C, McGlade A, Doecke JD et al. Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease. *Front Neurol*. 2023;14:1072952. doi: <https://doi.org/10.3389/fneur.2023.1072952>.
7. Schmitz M, Villar-Piqué A, Hermann P, Escaramís G, Calero M, Chen C et al. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. *Brain*. 2022;145(2):700–12. doi: <https://doi.org/10.1093/brain/awab350>.
8. Chen ZY, Chu M, Liu L, Zhang J, Kong Y, Xie K et al. Genetic prion diseases presenting as frontotemporal dementia: clinical features and diagnostic challenge. *Alzheimers Res Ther*. 2022;14(1):90. doi: <https://doi.org/10.1186/s13195-022-01033-4>.
9. Nan H, Liu L, Chen Z, Chu M, Li J, Jing D et al. Octapeptide repeat alteration mutations of the prion protein gene in clinically diagnosed Alzheimer's disease and frontotemporal dementia. *Clin Genet*. 2023;104(3):350–5. doi: <https://doi.org/10.1111/cge.14354>.
10. Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. *Lancet*. 2002;360(9327):139–41. doi: [https://doi.org/10.1016/S0140-6736\(02\)09384-4](https://doi.org/10.1016/S0140-6736(02)09384-4).
11. Collins S, Boyd A, Fletcher A, Kaldor J, Hill A, Farish S et al. Creutzfeldt-Jakob disease cluster in an Australian rural city. *Ann Neurol*. 2002;52(1):115–8. doi: <https://doi.org/10.1002/ana.10224>.
12. Klug GM, Wand H, Boyd A, Law M, Whyte S, Kaldor J et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. *Brain*. 2009;132(2):493–501. doi: <https://doi.org/10.1093/brain/awn303>.
13. Stevenson M, Uttley L, Oakley JE, Carroll C, Chick SE, Wong R. Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review. *Health Technol Assess*. 2020;24(11):1–150. doi: <https://doi.org/10.3310/hta24110>.
14. Watson N, Brandel JP, Green A, Hermann P, Ladogana A, Lindsay T et al. The importance of ongoing international surveillance for Creutzfeldt-Jakob disease. *Nat Rev Neurol*. 2021;17(6):362–79. doi: <https://doi.org/10.1038/s41582-021-00488-7>.
15. (a) Barber D, Trost N, Stehmann C, Lewis V, Doecke J, Jhamb A et al. Assessing the newly proposed MRI criteria for diagnosing sporadic Creutzfeldt-Jakob disease. *Neuroradiology*. 2024;66(11):1907–15. doi: <https://doi.org/10.1007/s00234-024-03440-w>. (b) (ibid) Erratum. *Neuroradiology*. 2024v;66(11):2089. doi: <https://doi.org/10.1007/s00234-024-03455-3>.

16. The Royal College of Pathologists of Australasia Autopsy Working Party. The decline of the hospital autopsy: a safety and quality issue for healthcare in Australia. *Med J Aust.* 2004;180(6):281–5. doi: <https://doi.org/10.5694/j.1326-5377.2004.tb05926.x>.
17. Jackett L, McLean C. Hospital autopsy remains a vital instrument for quality assurance of clinical diagnosis. *Pathology.* 2014;46(Suppl 1):S56. doi: <https://doi.org/10.1097/01.PAT.0000443521.56495.1a>.
18. Panegyres PK, Stehmann C, Klug GM, Masters CL, Collins S. Prion disease in Indigenous Australians. *Intern Med J.* 2021;51(7):1101–5. doi: <https://doi.org/10.1111/imj.14835>.
19. Mok T, Jaunmuktane Z, Joiner S, Campbell T, Morgan C, Wakerley B et al. Variant Creutzfeldt–Jakob disease in a patient with heterozygosity at PRNP codon 129. *N Engl J Med.* 2017;376(3):292–4. doi: <https://doi.org/10.1056/NEJMc1610003>.
20. Brandel JP, Vlaicu MB, Culeux A, Belondrade M, Bougard D, Grznarova K et al. Variant Creutzfeldt–Jakob disease diagnosed 7.5 years after occupational exposure. *N Engl J Med.* 2020;383(1):83–5. doi: <https://doi.org/10.1056/NEJMc2000687>.
21. Alnakhli SH, Wand H, Law M, Sarros S, Stehmann C, Senesi M et al. Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. *J Clin Neurosci.* 2020;81:78–82. doi: <https://doi.org/10.1016/j.jocn.2020.09.021>.
22. Cali I, Cohen ML, Haïk S, Parchi P, Giaccone G, Collins SJ et al. Iatrogenic Creutzfeldt–Jakob disease with Amyloid- β pathology: an international study. *Acta Neuropathol Commun.* 2018;6(1):5. doi: <https://doi.org/10.1186/s40478-017-0503-z>.
23. Purro SA, Farrow MA, Linehan J, Nazari T, Thomas DX, Chen Z et al. Transmission of amyloid- β protein pathology from cadaveric pituitary growth hormone. *Nature.* 2018;564(7736):415–9. doi: <https://doi.org/10.1038/s41586-018-0790-y>.
24. Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath C et al. Evidence of amyloid- β cerebral amyloid angiopathy transmission through neurosurgery. *Acta Neuropathol.* 2018;135(5):671–9. doi: <https://doi.org/10.1007/s00401-018-1822-2>.
25. Banerjee G, Adams ME, Jaunmuktane Z, Lammie GA, Turner B, Wani M et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. *Ann Neurol.* 2019;85(2):284–90. doi: <https://doi.org/10.1002/ana.25407>.
26. Banerjee G, Farmer SF, Hyare H, Jaunmuktane Z, Mead S, Ryan NS et al. Iatrogenic Alzheimer’s disease in recipients of cadaveric pituitary-derived growth hormone. *Nat Med.* 2024;30(2):392–402. doi: <https://doi.org/10.1038/s41591-023-02729-2>.
27. Kellie JF, Campbell BCV, Watson R, Praeger AJ, Nair G, Murugasu A et al. Amyloid- β (A β)-related cerebral amyloid angiopathy causing lobar hemorrhage decades after childhood neurosurgery. *Stroke.* 2022;53(8):E369–74. doi: <https://doi.org/10.1161/STROKEAHA.121.038364>.

Appendix A

EUROCJD diagnostic criteria for surveillance of sporadic CJD from 1 January 2017

Definite:

Progressive neurological syndrome AND Neuropathologically or immunohistochemically or biochemically confirmed

Probable:

I + two of II and typical EEG^a

OR

1.2.2 I + two of II and typical MRI brain scan^b

OR

1.2.3 I + two of II and positive CSF 14-3-3

OR

1.2.4 Progressive neurological syndrome and positive RT-QuIC in CSF or other tissues

Possible:

I + two of II + duration < 2 years

I Rapid progressive cognitive impairment

II A Myoclonus

B Visual or cerebellar problems

C Pyramidal or extrapyramidal features

D Akinetic mutism

a EEG: electroencephalogram; generalised periodic complexes.

b High signal in caudate/putamen and MRI brain scan or at least two cortical regions (temporal, parietal, occipital) either on diffusion-weighted imaging (DWI) or fluid attenuated inversion recovery (FLAIR).